Fictive Impurity Models: an Alternative Formulation of the Cluster Dynamical Mean Field Method

"Cluster" extensions of the dynamical mean field method to include longer range correlations are discussed. It is argued that the clusters arising in these methods are naturally interpreted not as actual subunits of a physical lattice but as algorithms for computing coefficients in an orthogonal function expansion of the momentum dependence of the electronic self-energy. The difficulties with causality which have been found to plague cluster dynamical mean field methods are shown to be related to the "ringing" phenomenon familiar from Fourier analysis. The analogy is used to motivate proposals for simple filtering methods to circumvent them. The formalism is tested by comparison to low order perturbative calculations and self consistent solutions

Cluster Dynamical Mean Field Theories

Cluster Dynamical Mean Field Theories are analyzed in terms of their semiclassical limit and their causality properties, and a translation invariant formulation of the cellular dynamical mean field theory, PCDMFT, is presented. The semiclassical limit of the cluster methods is analyzed by applying them to the Falikov-Kimball model in the limit of infinite Hubbard interaction U where they map to different classical cluster schemes for the Ising model. Furthermore the Cutkosky-t'Hooft-Veltman cutting equations are generalized and derived for non translation invariant systems using the Schwinger-Keldysh formalism. This provides a general setting to discuss causality properties of cluster methods. To illustrate the method, we prove that PCDMFT is causal while the nested cluster schemes (NCS) in general and the pair scheme in particular are not. Constraints on further extension of these schemes are discussed.Comment: 26 page

Neutral-ionic phase transition : a thorough ab-initio study of TTF-CA

The prototype compound for the neutral-ionic phase transition, namely TTF-CA, is theoretically investigated by first-principles density functional theory calculations. The study is based on three neutron diffraction structures collected at 40, 90 and 300 K (Le Cointe et al., Phys. Rev. B 51, 3374 (1995)). By means of a topological analysis of the total charge densities, we provide a very precise picture of intra and inter-chain interactions. Moreover, our calculations reveal that the thermal lattice contraction reduces the indirect band gap of this organic semi-conductor in the neutral phase, and nearly closes it in the vicinity of the transition temperature. A possible mechanism of the neutral-ionic phase transition is discussed. The charge transfer from TTF to CA is also derived by using three different technics.Comment: 11 pages, 9 figures, 7 table

Phonon driven transport in amorphous semiconductors: Transition probabilities

Inspired by Holstein's work on small polaron hopping, the evolution equations of localized states and extended states in presence of atomic vibrations are derived for an amorphous semiconductor. The transition probabilities are obtained for four types of transitions: from one localized state to another localized state, from a localized state to an extended state, from an extended state to a localized state, and from one extended state to another extended state. At a temperature not too low, any process involving localized state is activated. The computed mobility of the transitions between localized states agrees with the observed `hopping mobility'. We suggest that the observed `drift mobility' originates from the transitions from localized states to extended states. Analysis of the transition probability from an extended state to a localized state suggests that there exists a short-lifetime belt of extended states inside conduction band or valence band. It agrees with the fact that photoluminescence lifetime decreases with frequency in a-Si/SiO$_{2}$ quantum well while photoluminescence lifetime is not sensitive to frequency in c-Si/SiO$_{2}$ structure.Comment: 41 pages, 3 figures, submitted to Phys. Rev.

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362